报价延迟最少15分钟:2025/07/21 06:47 EDT
盘前时段
|
||||
|
2.02 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.99
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.85/-2.91
|
|
企业价值
119.81M
|
| 资产负债 |
|
每股账面净值
5.69
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
52.30M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:47 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others. |
